News

Novoclem’s Candidate Therapy Shows Promise Against 9 Pathogens Associated with Cystic Fibrosis Infection

Novoclem Therapeutics’ lead drug candidate, a nitric oxide-releasing biopolymer, can eliminate nine of the most prevalent microorganisms responsible for severe lung infections in cystic fibrosis (CF) patients, the Morrisville, N.C., company reported. “Our mission is to arm patients with therapies that treat resistant bacteria and enable them to breathe…

Polyphor Secures $40 Million for Late-Stage Development of Murepavadin for CF Airway Infections

Swiss-based Polyphor has secured financing for late-stage development of Murepavadin (POL7080), an antibiotic targeting a bacteria that often infects the airways of cystic fibrosis (CF) patients. A hallmark of the therapy is that it goes after antibiotic-resistant strains of Pseudomonas aeruginosa, which infects not just MS patients, but people with other…

Enterprise Therapeutics Gets Cystic Fibrosis Trust Grant to Develop Innovative Treatments

Enterprise Therapeutics has received a £95,000 grant from Britain’s Cystic Fibrosis Trust to develop innovative treatments for cystic fibrosis (CF). The money, equivalent to $118,000, will support the development of CF therapies based on Enterprise Therapeutics’ bronchosphere technology platform. Cystic fibrosis blocks airway passages. The condition stems from faulty airway-surface…

ProQR’s Cystic Fibrosis Therapy QR-010 Now Protected by U.S., European Patents Until 2033

Dutch pharmaceutical company ProQR Therapeutics now has two key patents protecting its first-in-class ribonucleic acid (RNA)-based oligonucleotide QR-010 for the treatment of cystic fibrosis (CF) in the United States and Europe. The patents are valid until at least July 2033. The new U.S. patent, announced April 3, covers methods of targeting…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.